← Eichor
Study identifier: NCT06546761 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Selective Coronary Revascularization in Carotid Artery Disease Patients After Carotid Revascularization (SCORECAD Trial)

Condition: Carotid Stenosis · Coronary Artery Disease  ·  Sponsor: Pauls Stradins Clinical University Hospital

PhaseN/A
Planned participants300
Who can joinAll sexes, 50 Years to no upper limit
Healthy volunteersNo

About this study

The primary objective of this study is to determine whether among symptomatic and asymptomatic carotid artery stenosis (CAS) patients with no known coronary artery disease (CAD) who had undergone carotid artery revascularization (endarterectomy of stenting) a strategy of best medical therapy (BMT) plus selective coronary revascularization based on FFRct assessment of lesion-specific coronary ischemia can reduce adverse cardiac events and improve survival compared to BMT alone. Lesion-specific coronary ischemia is defined as FFRCT ≤0.80 distal to stenosis in a major (≥2 mm) coronary artery with severe ischemia defined as FFRCT ≤0.75.

This description comes directly from the study's public registry record.

Talk to the study team

Dainis Krievins, MD, PhD  ·  +371 29450000  ·  dainis.krievins@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Pauls Stradins Clinical University HospitalRiga, LatviaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06546761